ADMA Biologics (ADMA) Projected to Post Quarterly Earnings on Wednesday

ADMA Biologics (NASDAQ:ADMA) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.15 per share and revenue of $112.80 million for the quarter.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $15.84 on Monday. ADMA Biologics has a 52 week low of $5.08 and a 52 week high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a market cap of $3.74 billion, a P/E ratio of 56.57 and a beta of 0.75. The stock has a 50 day moving average of $16.97 and a 200-day moving average of $18.00.

Analyst Upgrades and Downgrades

A number of research firms have commented on ADMA. HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Raymond James upped their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.